Maarten C.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- Phase III Randomized, Placebo-Controlled Study of Venetoclax with Induction and Consolidation Chemotherapy in Newly Diagnosed AML or MDS-EB2 Patients
- Evaluation of Revumenib Combined with Azacitidine and Venetoclax in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML Patients Ineligible for Intensive Chemotherapy
- HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study
Data & Insights
Has run more than one trial at 119 of 252 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating acute myeloid leukemia (AML), with particular emphasis on newly diagnosed cases and innovative therapeutic approaches.
- IDH1-mutated AML management
- Treatment strategies for intensive chemotherapy-ineligible patients
- Novel combination therapies
Additional focus includes studying treatment outcomes in patients with myelodysplastic syndrome with excess blasts-2.
Targeted Therapies
Expertise in implementing targeted therapeutic approaches using molecular inhibitors and novel agents in hematologic conditions.
- Ivosidenib-based combinations
- Venetoclax applications
- Azacitidine combinations
Specialized interest in developing treatment protocols for specific genetic mutations in blood cancers.
Treatment Innovation
Focus on advancing induction and consolidation therapy approaches for hematologic malignancies.
- Novel therapeutic combinations
- Treatment optimization strategies
- Patient-specific approaches
Particular attention to developing treatments for patients with specific genetic markers and varying fitness levels.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.